IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY

被引：0
|
作者：
Trneny, M. [1 ]
Lamy, T. [2 ]
Walewski, J. [3 ,4 ]
Belada, D. [5 ,6 ]
Mayer, J. [7 ]
Radford, J. [8 ,9 ]
Jurczak, W. [10 ]
Morschhauser, F. [11 ]
Alexeeva, J. [12 ]
Rule, S. [13 ]
Biyukov, T. [14 ]
Patturajan, M. [15 ]
Bravo, M. L. Casadebaig [14 ]
Arcaini, L. [16 ,17 ]
机构：
[1] Charles Univ Hosp, Dept Hematol, Prague, Czech Republic
[2] Hop Pontchaillou, Dept Hematol, Rennes, France
[3] Maria Sklodowska Curie Mem Inst Oncol, Dept Lymphoid Malignancies, Warsaw, Poland
[4] Ctr Oncol, Warsaw, Poland
[5] Charles Univ Hosp, Dept Internal Med Haematol 4, Hradec Kralove, Czech Republic
[6] Fac Med, Hradec Kralove, Czech Republic
[7] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[8] Univ Manchester, Dept Med Oncol, Manchester, Lancs, England
[9] Christie NHS Fdn Trust, Manchester, Lancs, England
[10] Jagiellonian Univ, Dept Hematol, Krakow, Poland
[11] Ctr Hosp Univ Reg Lille, Lille, France
[12] Fed Med Res Ctr, St Petersburg, Russia
[13] Derriford Hosp, Dept Haematol, Plymouth PL6 8DH, Devon, England
[14] Celgene Int Sarl, Boudry, Switzerland
[15] Celgene Corp, Summit, NJ USA
[16] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[17] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S107
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [41] A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
    Ando, Kiyoshi
    Ogura, Michinori
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Kim, Won Seog
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Updated Safety and Efficacy including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study
    Cohen, Jonathon B.
    Shah, Nirav N.
    Jurczak, Wojciech
    Zinzani, Pier Luigi
    Cheah, Chan Y.
    Eyre, Toby A.
    Ujjani, Chaitra S.
    Koh, Youngil
    Kim, Won Seog
    Nasta, Sunita D.
    Flinn, Ian
    Tessoulin, Benoit
    Shuo, M. A.
    Alencar, Alvaro J.
    Lewis, David J.
    Woyach, Jennifer A.
    Maddocks, Kami J.
    Patel, Krish
    Wang, Yucai
    Rhodes, Joanna
    Tam, Constantine S.
    Seymour, John F.
    Nagai, Hirokazu
    Vose, Julie M.
    Fakhri, Bita
    Hoffmann, Marc S.
    Hernandez-Ilizaliturr, Francisco
    Zelenetz, Andrew D.
    Kumar, Anita
    Munir, Talha
    Tsai, Donald
    Balbas, Minna
    Liu, Bin
    Ruppert, Amy S.
    Nguyen, Bastien
    Roeker, Lindsey E.
    Wang, Michael L.
    Dreyling, Martin
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 119 - 120
  • [43] PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
    Burke, J. M.
    Andorsky, D. J.
    Yacoub, A.
    Melear, J.
    Coleman, M.
    Kolibaba, K.
    Brooks, H.
    Bitran, J.
    Fanning, S.
    Lansigan, F.
    Ricker, J. L.
    Foon, K.
    Llorente, M.
    Li, J.
    Sharman, J.
    HAEMATOLOGICA, 2017, 102 : 249 - 250
  • [44] A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma
    Blum, Kristie A.
    Baiocchi, Robert A.
    Alinari, Lapo
    Lin, Thomas S.
    Porcu, Pierluigi
    Jones, Jeffrey
    Flynn, Joseph
    Hicks, William
    Lucas, Margaret S.
    Wei, Lai
    Johnston, Jeffrey S.
    Byrd, John C.
    BLOOD, 2008, 112 (11) : 1049 - 1050
  • [45] Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study
    Yamshon, Samuel
    Martin, Peter
    Shah, Bijal
    Schuster, Stephen J.
    Christos, Paul J.
    Rodriguez, Amelyn
    Smith, Sonali M.
    Svoboda, Jakub
    Furman, Richard R.
    Rutherford, Sarah C.
    Allan, John N.
    Leonard, John P.
    Ruan, Jia
    BLOOD, 2020, 136
  • [46] Glofitamab Monotherapy In Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Updated Analysis From A Phase 1/2 Study
    Phillips, Tycel
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    de L'Etang, Audrey Filezac
    Relf, James
    Carlile, David J.
    Byrne, Ben
    Mulvihill, Estefania
    Lundberg, Linda
    Dickinson, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S515 - S516
  • [47] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
    Wang, Michael
    Jurczak, Wojciech
    Trneny, Marek
    Belada, David
    Wrobel, Tomasz
    Ghosh, Nilanjan
    Keating, Mary-Margaret
    van Meerten, Tom
    Alvarez, Ruben Fernandez
    von Keudell, Gottfried
    Thieblemont, Catherine
    Peyrade, Frederic
    Andre, Marc
    Hoffmann, Marc
    Glusman, Edith Szafer
    Lin, Jennifer
    Dean, James P.
    Neuenburg, Jutta K.
    Tam, Constantine S.
    BLOOD, 2023, 142
  • [48] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
    Wang, Michael
    Jurczak, Wojciech
    Trneny, Marek
    Belada, David
    Wrobel, Tomasz
    Ghosh, Nilanjan
    Keating, Mary-Margaret
    van Meerten, Tom
    Fernandez Alvarez, Ruben
    von Keudell, Gottfried
    Thieblemont, Catherine
    Peyrade, Frederic
    Andre, Marc
    Hoffmann, Marc
    Glusman, Edith Szafer
    Lin, Jennifer
    Dean, James P.
    Neuenburg, Jutta K.
    Tam, Constantine S.
    BLOOD, 2024, 144 : LBA5 - LBA5
  • [49] Five-year subgroup analysis of tafasitamab plus lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
    Duell, Johannes
    Abrisqueta, Pau
    Dreyling, Martin H.
    Gaidano, Gianluca
    Barca, Eva Gonzalez
    Jurczak, Wojciech
    Maddocks, Kami J.
    Menne, Tobias
    Tournilhac, Olivier
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles A.
    Nagy, Zsolt
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Five-Year Subgroup Analysis of Tafasitamab plus Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Duell, Johannes
    Abrisqueta, Pau
    Dreyling, Martin
    Gaidano, Gianluca
    Gonzalez Barca, Eva
    Jurczak, Wojciech
    Maddocks, Kami J.
    Menne, Tobias
    Nagy, Zsolt
    Tournilhac, Olivier
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S436 - S437
12345